-
2022-501562-22-00
4
Triple-negative breast cancer (TNBC) patients at high risk of relapse
-
2022-502126-40-00
5
HIV-1 infection
-
2023-503170-20-00
1
Advanced solid tumors
-
2023-508476-11-00
1
Adenoid cystic carcinoma (ACC)
-
2023-508784-68-00
10
metastatic uveal melanoma
-
2023-509392-17-00
5
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-511595-32-00
6
Acute low back pain
-
2024-512511-49-00
4
Early triple-negative breast cancer (TNBC)
-
2024-513724-42-00
10
Medulloblastoma
-
2024-513889-19-00
5
Multiple Myeloma
-
2024-514144-85-02
3
Glioblastoma
-
2024-514243-29-01
5
This is a prospective, French, multicenter, open-label, design, strati
-
2024-515362-13-00
10
Philadelphia-negative myeloproliferative neoplasms are frequent and ch
-
2024-516052-17-01
10
Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
-
2024-516097-30-00
6
Community acquired pneumonia (CAP)
-
2024-516115-24-00
9
High risk relapsed neuroblastoma (relapsed or progressed after being d
-
2024-516182-37-01
4
Maintenance treatment in patients with locally advanced/metastatic uro
-
2024-516328-32-00
4
CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
-
2024-517339-30-00
7
Advanced Solid Tumors
-
2024-518138-10-00
4
Patients with DMMR and/or MSI metastatic colorectal cancer
-
2024-518139-12-00
4
locally advanced or metastatic Pancreatic ductal adenocarcinoma
-
2024-518199-30-00
9
Soft tissue sarcoma patients
-
2024-518326-32-00
7
Patients with advanced solid malignancies that have progressed followi
-
2024-518871-74-00
4
Locally Advanced or Metastatic Solid Tumours that harbour MET Amplific